NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 87)
Posted On: 04/15/2024 4:13:02 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Concentrating 2024 R&D Plans Mainly on GLP-1 Investigations
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced $3.6 million in gross proceeds from its registered direct offering. “Most notably, Lexaria intends to use the net proceeds from this offering for research and development (‘R&D’) studies and the associated patent and legal costs. It also intends to use the funds for general working capital purposes, important for its current focus on GLP-1 clinical studies for the 2024 calendar year… In 2023, Lexaria laid the groundwork for its GLP-1 clinical studies. The company achieved positive interim and final human pilot study results using a single semaglutide dose of a Rybelsus(R) tablet to a matching dose of Rybelsus that had been processed with DehydraTECH(TM) enhancements… These results inspired the confidence of Lexaria’s team,” a recent article reads. “Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations,” Chris Bunka, Lexaria’s CEO, is quoted as saying.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced $3.6 million in gross proceeds from its registered direct offering. “Most notably, Lexaria intends to use the net proceeds from this offering for research and development (‘R&D’) studies and the associated patent and legal costs. It also intends to use the funds for general working capital purposes, important for its current focus on GLP-1 clinical studies for the 2024 calendar year… In 2023, Lexaria laid the groundwork for its GLP-1 clinical studies. The company achieved positive interim and final human pilot study results using a single semaglutide dose of a Rybelsus(R) tablet to a matching dose of Rybelsus that had been processed with DehydraTECH(TM) enhancements… These results inspired the confidence of Lexaria’s team,” a recent article reads. “Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations,” Chris Bunka, Lexaria’s CEO, is quoted as saying.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼